Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community by Minnema, L. A. et al.
Adverse events related to biologicals used for patients with multiple
sclerosis: a comparison between information originating from
regulators and information originating from the scientific community
L. A. Minnemaa,b , T. J. Giezenb,c,d, T. C. G. Egbertsa,e, H. G. M. Leufkensa and H. Gardarsdottira,e,f
aDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University,
Utrecht; bMedicines Evaluation Board, Utrecht; cFoundation Pharmacy for Hospitals in Haarlem, Haarlem; dSpaarne Gasthuis, Haarlem;
eDepartment of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands; and fDepartment of Pharmaceutical








Received 2 October 2019
revision requested 24
December 2019
Accepted 4 April 2020
European Journal of
Neurology 2020, 27: 1250–
1256
doi:10.1111/ene.14259
Background and purpose: Clinical decision making is facilitated by healthcare
professionals’ and patients’ adequate knowledge of the adverse events. This is
especially important for biologicals used for treating multiple sclerosis (MS).
So far, little is known about whether different information sources report
adverse events consistently.
Methods: Biologicals authorized by the European Medicines Agency for the
treatment of MS were included in this study. Information on adverse events
derived from phase 3 clinical trials from European Public Assessment Reports
(EPARs) and from scientific publications was compared.
Results: In the study, eight biologicals used for the treatment of MS were
included for which the EPAR and/or scientific publication reported a total of
707 adverse events. Approximately one-third of the adverse events was
reported in both the EPAR and scientific publication, one-third was only
reported in the EPAR and one-third only in the scientific publication. Serious
adverse events and adverse events that regulators classified as ‘important iden-
tified risk’ were significantly more often reported in both sources compared to
adverse events not classified as such (respectively, 38% vs. 30% and 49% vs.
30%). Adverse events only reported in the EPAR or in the scientific publica-
tion were, in general, not described in the benefit–risk section or abstract,
which were considered to be the most important sections of the documents.
Conclusions: This study showed that there is substantial discordance in the
reporting of adverse events on the same phase 3 trials between EPARs and sci-
entific publications. To support optimal clinical decision making, both docu-
ments should be considered.
Introduction
Regulators have approved several biologicals to treat
patients with relapsing and progressive multiple sclero-
sis (MS) during the last decade. Although these biologi-
cals improve clinical symptoms and reduce relapse rates
and disease progression, serious adverse events (SAEs)
can occur. The detection of the adverse events (AEs) of
these drugs may be complicated as these AEs can mimic
the clinical expression of MS. For example, the early
symptoms of encephalitis associated with the use of
daclizumab include aphasia, confusion and disorienta-
tion, which are symptoms similar to those associated
with a serious MS relapse [1]. Encephalitis was there-
fore first interpreted as a worsening of the disease and
as lack of efficacy of the drug instead of a SAE [1].
Healthcare professionals and patients can use different
sources of information to obtain knowledge about the
efficacy and safety profile of a drug in order to guide
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clinical decision making. At the time of approval, knowl-
edge about the efficacy and safety profile is mainly based
on the findings of the phase 3 randomized clinical trials
that supported marketing approval. The results of these
clinical trials are (publicly) available in various informa-
tion sources. One of these information sources is peer-re-
viewed scientific publications where investigators report
the results of the clinical trials. These scientific publica-
tions were an important source of evidence for the devel-
opment of the European Clinical Guideline on the
pharmacological treatment of people with MS [2].
Another source is the publicly available European Public
Assessment Report (EPAR). The European Medicines
Agency (EMA), which is the regulatory authority in Eur-
ope responsible for evaluating marketing approval appli-
cations, publishes the EPAR; it provides an overview of
the assessment procedure, including an assessment of the
conducted clinical trials [3].
Although these two information sources reflect
information obtained from the same clinical trials, the
choice of the clinical findings that are extracted from
these trials and the attention given to those clinical
findings can differ. However, one might expect that the
most important information generated from the clini-
cal trials is reported in both documents. Several studies
have assessed synergies between the reporting of effi-
cacy and safety information from clinical trials by reg-
ulatory authorities and in scientific publications [4-9].
These show that there are large differences in reporting
between these two types of information sources. For
example, de Vries et al. [5] showed that, for antidepres-
sants, 79% of the scientific publications provided
incomplete information on SAEs compared to data
obtained from the US Food and Drug Administration,
and 63% did not mention SAEs at all. Another study
on insomnia medication showed that scientific publica-
tions from studies identified in the EPAR reported reli-
ably on the primary end-points but less reliably or not
at all on the safety of the drug [6].
Since SAEs have occurred in clinical practice for
biologicals used for MS, clinicians should have a com-
prehensive view of the safety profile to support clinical
decision making. Therefore, the aim of this study was
to provide, for biologicals used in MS, an analysis on
which AEs from clinical trials are reported in the
EPARs and the corresponding scientific publications,
and whether these differ.
Methods
Study drugs and information sources
In this study, biologicals that were or had been
approved by the EMA for the treatment of MS (as of
31 December 2018) were included. The EPARs were
retrieved from the EMA website (www.ema.europa.e
u). The corresponding scientific publications of the
phase 3 randomized clinical trials that supported
approval of the product were identified using PubMed
and the webpage clinicaltrials.gov. The full text of the
scientific publication was obtained from the scientific
journal concerned. Whether the scientific publications
corresponded with the clinical trials described in the
EPARs was verified by comparing the identifiers used
in the EPARs and scientific publications (e.g. the clin-
icaltrials.gov identifier), the study design and the num-
ber of patients included. Furthermore, a cross-check
with the Cochrane review on immunomodulators and
immunosuppressants for relapsing–remitting MS was
performed [10].
For each product, information on the year of
approval, number of clinical trials supporting the
approval of the product, and mechanism of action
from the EPAR was retrieved.
Adverse events
For both information sources, the reported AEs for
each product were compared. For the EPAR, the
analysis was limited to the sections reporting on the
safety information from the clinical trials and the ben-
efit–risk discussion, whereas for the scientific publica-
tions all sections (including appendices, if applicable)
were taken into account.
The AEs reported for the product were identified
and characterized using the Medical Dictionary for
Regulatory Affairs (MedDRA) [11]. MedDRA is a
validated standardized terminology used to facilitate
the exchange of information on AEs, and it is used,
amongst other things, in the communication of infor-
mation from clinical trials between industry and regu-
lators. MedDRA is hierarchically structured. The
lowest, and most specific, level reflects how an AE is
reported in practice. Each of these lower level terms is
linked to one preferred term. Multiple lower level
terms can fall within one preferred term, as they may
include synonyms or different word forms for the
same expression. For example, the lower level terms
‘multiple sclerosis exacerbation’ and ‘multiple sclerosis
flare’ fall within the same preferred term ‘multiple
sclerosis relapse’. For this study, the consistency in
the reporting of AEs was assessed by comparing the
AEs on the preferred term level. The AEs were also
grouped according to the highest level of the Med-
DRA hierarchy, namely the System Organ Class
level.
In addition, various characteristics of the reported
AEs were assessed as follows.
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• Attention: An assessment was made of where in the
text the authors described the AE. For the EPAR,
it was assessed whether the regulators described the
AE in the concluding section that reports how the
benefits are weighted against the risks. For the sci-
entific publications, it was assessed whether
researchers described the AE in the abstract, main
body of the text, a table and/or an appendix.
• Seriousness: Adverse events were categorized as a
SAE if the authors specifically described the AE as
being serious or if an AE was listed on the impor-
tant medical events list of the EMA [12]. An SAE is
an AE that results in death, is life-threatening,
requires hospitalization or prolongs existing hospi-
talization, results in persistent or significant disabil-
ity, or is a birth defect. This definition is also
included in the guidelines for scientific publications.
• Regulatory importance: Adverse events were catego-
rized as regulatory important if regulators included
these as important risks in the risk management plan
(RMP). A separate chapter of the EPAR describes
the RMP, including the important identified risks.
Regulators include safety issues as important identi-
fied risks in the RMP if these have been causally asso-
ciated with the product, should be further
characterized after marketing approval, and are likely
to have an impact on the benefit–risk balance [13]. As
the EMA introduced RMPs in 2005, this information
could not be included for the products authorized
prior to 2005.
Data analysis
Whether the EPAR and scientific publication report
consistently on AEs for the same biological was
assessed by comparing these on the preferred term
level. In the EPAR, when the authors referred to a
pooled analysis of data, it was considered to be con-
sistently reported if the AE was reported in at least
one of the scientific publications. The frequencies of
AEs that were consistently reported in both the EPAR
and scientific publication, those that were only
reported in the EPAR, and those that were only
reported in the scientific publication were calculated.
Relative risks (including 95% confidence intervals)
were calculated to assess the association of the charac-
teristics of the AE described above and the consis-
tency in reporting of the AE in both the EPAR and
scientific publication.
Statistical analysis was performed using R statistical
software version 3.6.0 (R Core Team, Vienna, Austria).
Results
As of 31 December 2018, the EMA had approved
nine biologicals for the treatment of MS. From these
nine products, one [Extavia (interferon-b-1b)] was
excluded from the analysis as the company used the
same dossier of the already available Betaferon for
the marketing approval. Although the company has
taken Zinbryta (daclizumab) off the market in
March 2018, it was included in the analysis as only
the information available at the time of regulatory
approval was taken into account. As a result, eight
biologicals were included in this study (Table 1). For
all the products, the results of the phase 3 clinical tri-
als were published in the scientific literature.
Consistency in reporting of AEs
The EPARs and/or the scientific publications reported
707 AEs. A comparable number of different AEs was
reported for the interferons Avonex (n = 23), Rebif
(n = 38) and Betaferon (n = 33), whereas a consider-
ably higher number was reported for the peginterferon
product Plegridy (n = 103). For the monoclonal anti-
bodies, the number of AEs ranged from 108 for Ocre-
vus to 174 for Lemtrada.
Overall, the proportion of AEs consistently
reported in both the EPAR and scientific publication
was 35%. Amongst the interferons, the proportion
ranged from 27% for Betaferon to 35% for Avo-
nex (Fig. 1). For the monoclonal antibodies, the pro-
portion of AEs consistently reported in both
Table 1 Biologicals authorized by the European Medicines Agency (EMA) for the treatment of multiple sclerosis included in this study
Product name Active substance Year of EMA approval Number of trials supporting the approval Mechanism of action
Betaferon Interferon-b-1b 1995 1 Immunomodulating cytokine
Avonex Interferon-b-1a 1997 1 Immunomodulating cytokine
Rebif Interferon-b-1a 1998 1 Immunomodulating cytokine
Tysabri Natalizumab 2006 2 Anti-a4-integrin
Lemtrada Alemtuzumab 2013 2 Anti-CD52
Plegridy Peginterferon-b-1a 2014 1 Immunomodulating cytokine
Zinbryta Daclizumab 2016 (withdrawn 2018) 2 Anti-CD25
Ocrevus Ocrelizumab 2018 3 Anti-CD20
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
1252 L. A. MINNEMA ET AL.
information sources ranged from 29% for Tysabri to
42% for Zinbryta (Fig. 1). Of the 707 reported AEs,
222 AEs (31%), of which 116 were SAEs, were only
described in the EPAR and not in the scientific publi-
cation. Accordingly, a total of 239 AEs (34%), of
which 123 were SAEs, were described only in the sci-
entific publication. Whether more AEs were described
in either the EPAR or the scientific publication dif-
fered per product. For example, for Plegridy, 63%
of the AEs were described only in the EPAR, whereas
for Tysabri, 53% of the AEs were described only in
the scientific publication.
Of the 222 AEs that were described only in the
EPAR, 35 (16%) were described in the section dis-
cussing the benefit–risk balance. Of the 239 AEs
described only in the scientific publication, four AEs
(2%) were described in the abstract of the scientific
publication. The AEs were most often described in a
table (50%) or the text (35%).
Serious AEs were significantly (P < 0.05) more
often consistently reported in both the EPAR and sci-
entific publication compared to non-serious AEs (38%
vs. 30%, relative risk 1.23, 95% confidence interval
1.00–1.52) (Table 2). Also, AEs that regulators classi-
fied as important identified risk were significantly
more often consistently reported in both documents
compared to those that authorities did not classify as
such (49% vs. 30%, relative risk 1.65, 95% confidence
interval 1.34–2.03).
Nature of the reported AEs
In line with the known safety profile of the products,
most AEs were infections and infestations (n = 145,
21%), followed by investigations (n = 94, 13%) and
general disorders and administration site conditions
(n = 70, 10%). For these categories, the consistency in
reporting of the AEs ranged from 39% for infections
and infestations to 49% for general disorders and
administration site conditions.
The pattern of reporting SAEs in specific categories
differed per product. For Avonex, Betaferon and
Rebif, it was not possible to observe any differences
as a limited number of SAEs were reported. For Ple-
gridy, it was observed that five SAEs, classified as
neoplasms benign, malignant and unspecified (includ-
ing cysts and polyps), were only described in the
EPAR. For the monoclonal antibodies, additional
SAEs were reported in the EPAR and scientific publi-
cation that were related to the mechanism of action
(i.e. infections and infestations) besides the SAEs that
were reported in both documents. However, it was
also observed that SAEs in specific categories (e.g.
vascular disorders, neoplasms benign, malignant and
unspecified) were only described in either one of the
documents.
Discussion
The current study provided a comparison of AEs
reported in EPARs and scientific publications. Over-
all, approximately one-third of the AEs was consis-
tently reported in both the EPAR and scientific
publication, one-third in the EPAR only, and one-
third in the scientific publication only. The results
indicate ample discordance in the reporting of AEs
between EPARs and scientific publications. However,
the AEs that were reported in the EPAR or scientific
publication only were, in general, not described in the
most important sections of the documents, i.e.
abstract or benefit–risk section. Also, SAEs and events
that regulators classified as important identified risks
were more often consistently reported. Therefore, both
documents probably reflect the safety information that
is key to the benefit–risk of the product and clinical
decision making, whereas a complete overview of the
AEs is lacking. This might have implications for the
information presented in the clinical guidelines,
including the guidelines for treatment of MS, as these
are mainly based on the information that is described
in the scientific publications [2]. It is recommended
that information from the regulators be incorporated
during the development of clinical guidelines. How-
ever, the EPAR may also not reflect the complete
safety profile of the product, as approximately one-
third of the AEs was only reported in scientific publi-
cations. As the EPAR is a reflection of the assessment
procedure, the regulators may have given specific
attention to AEs that were of major concern during
the assessment.
The proportion of AEs that was consistently
reported was comparable amongst the products. How-
ever, whether the proportion of AEs reported in either
one of the documents was higher for the EPAR or sci-
entific publication differed per product. When looking
into the nature of the AEs that were only reported in
one of the documents, it was observed that these were
mostly in line with the consistently reported AEs and
the AEs directly linked to the mechanism of action.
However, it was also observed that for some products
the authors did not report on a specific type of AE,
whereas the authors of the other information source
did.
In line with previous studies that compared infor-
mation from EPARs with scientific publications, there
are differences in the information provided by the reg-
ulators and the authors of scientific publications.
However, the proportion of safety information
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Figure 1 Venn diagrams displaying the number of AEs that were described in the EPAR and scientific publication
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
1254 L. A. MINNEMA ET AL.
missing in the scientific publications was lower in our
study compared to a previous study that performed a
high-level comparison (comparing specific AEs for
insomnia medication) of safety data, which reported
missing safety data in eight of the 15 scientific publi-
cations [7]. Also, a study that assessed reporting of
SAEs in scientific publications of antidepressants
found that 63% of the scientific articles did not men-
tion any SAEs [6]. These differences may be explained
by the difference in the nature of the products that
were included as, for example, more SAEs are associ-
ated with monoclonal antibodies used for treating MS
than with the use of insomnia medication. Given these
differences and as it was observed that the pattern of
reporting of AEs between EPARs and scientific publi-
cations differed per product, the results may not be
generalizable to other (types of) products.
For this study, all AEs that were reported at least
once were considered for the included biologicals in
the EPARs or scientific publications. As a causality
assessment on the AEs was not performed, AEs were
included that may not have been associated with the
product. Also, the extraction of the AEs from the text
might have been sensitive to interpretation in some
cases where the authors did not specifically state
whether the AE had been reported for the product
under study or whether the AE was considered to be
serious. However, this was minimized through consen-
sus amongst the authors on the interpretation of dif-
ferent scenarios reported in the EPARs and scientific
publications.
An in-depth comparison of AEs reported in the two
information sources is provided and these data are
put into perspective. Also, several studies considered
the information from regulators as the reference infor-
mation source. However, within this study it is shown
that scientific publications also contribute to a com-
plete overview of the AEs. These observations need
further research on how to align the information in
both sources more consistently.
Substantial discordance was observed in the AEs
reported on the same phase 3 trials of biologicals for
MS in information originating from regulators (de-
scribed in the EPAR) and the scientific community
(described in scientific publications). To support opti-
mal clinical decision making, healthcare professionals
and patients should consider both documents.
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